CERo Therapeutics Holdings, Inc. (CERO) stock
CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW
$0.01+0.00 (0.00%)
Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%
CERo Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2023 it was -$24972.80.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$24972.80 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.70 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.20 | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.10 | – |
| Q2 FY2025 | Jun 30, 2025 | -$61.71 | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.82 | – |
| Q3 FY2024 | Sep 30, 2024 | -$170.22 | – |
| Q2 FY2024 | Jun 30, 2024 | -$302.32 | – |
| Q3 FY2023 | Sep 30, 2023 | -$300.00 | – |
| Q2 FY2023 | Jun 30, 2023 | -$460.00 | – |
| Q1 FY2023 | Mar 31, 2023 | -$540.00 | – |
| Q3 FY2021 | Sep 30, 2021 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?